Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUSHMAH
2023-507010-27-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ACTH-independent macronodular adrenal hyperplasia (AIMAH), Cushing's syndrome, hypertension (HTN) and 1 more comparing Metyrapone with Placebo (2 arms). Primary endpoint: Improvement of blood pressure control and/or improvement of diabetes at 6 months. Planned start Mar 2026; status: authorised.
02
Drugs
metyrapone
03
Conditions
ACTH-independent macronodular adrenal hyperplasia (AIMAH)Cushing's syndromehypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-507010-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507010-27-00.